Trial Profile
Efficacy and safety of Sunitinib traditional and alternative treatment schedules in Japanese patients with metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jun 2016
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 14 Jan 2016 Status changed from not stated to completed.
- 16 Dec 2015 New trial record